Antiplatelet and anti-proliferative action of disintegrin from *Echis multisquamatis* snake venom

**Aim** To purify the platelet aggregation inhibitor from *Echis multisquamatis* snake venom (PAIEM) and characterize its effect on platelet aggregation and HeLa cell proliferation.

**Methods** Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) were used for PAIEM identification. Platelet aggregation in the presence of PAIEM was studied on aggregometer Solar-AP2110. The changes of shape and granularity of platelets in the presence of PAIEM were studied on flow cytometer COULTER EPICS XL, and degranulation of platelets was estimated using spectrofluorimetry. Indirect enzyme-linked immunosorbent assay was used for the determination of target of PAIEM on platelet surface. An assay based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was used to evaluate the effect of PAIEM on the proliferation of HeLa cells in cell culture.

**Results** The molecular weight of the protein purified from *Echis multisquamatis* venom was 14.9 kDa. Half-maximal inhibitory concentration (IC$_{50}$) of PAIEM needed to inhibit adenosine diphosphate (ADP)-induced platelet aggregation was 7 μM. PAIEM did not affect thrombin- or ADP-induced platelet activation, but it did prevent binding of the anti-IIb antibody to glycoprotein IIb/IIIa (GPIIbIIIa)-receptor of adhered platelets and inhibited the viability of HeLa cells by 54%.

**Conclusion** As a member of the disintegrin family, PAIEM inhibited platelet aggregation and cell proliferation possibly by blocking integrin-mediated interactions. However, it did not impair cellular signaling causing any changes in platelet shape and granularity and did not affect ADP-induced platelet degranulation. This disintegrin was shown to be a potent inhibitor of integrin-mediated cellular interactions including platelet aggregation or cancer cell proliferation.
Platelet aggregation represents a multistep adhesion process that is accompanied by fibrin polymerization and leads to thrombus formation (1). This multistep process is triggered by platelet interaction with the subendothelium extracellular matrix containing collagen and von Willebrand factor or by soluble inducers such as adenosine diphosphate (ADP), thrombin or thromboxane A$_2$ (2). Platelet aggregation inhibitors used as therapeutic drugs or laboratory reagents mainly target separate distinct stages of the process and can be divided into several groups. Purinergic receptors’ antagonists and well-known anti-platelet drugs ticagrelor, clopidogrel, prasugrel, and other similar drugs are used in clinical trials (3) and act mainly on P$_2$Y$_12$ ADP-receptor (4). Another common anti-platelet agent, aspirin, inhibits thromboxane A2 synthesis in platelets and thus reduces platelet response to agonists (5). There are many novel cyclooxygenase-2 inhibitors that are as potent as acetylsalicylic acid but still have some comparative disadvantages (6). Phosphodiesterase inhibitors decrease the hydrolysis of intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) and thus attenuate platelet aggregation (7). Some of them are already registered as therapeutic agents, such as cilostazol or dipyridamole.

Peptides and proteins that contain the Arg-Gly-Asp (RGD) sequence are able to inhibit the interaction between platelet glycoprotein IIb/IIIa (GPIIb/IIIa) and fibrinogen, preventing platelet aggregation (8). There are many GPIIb/IIIa antagonists in clinical use, such as abciximab, a Fab-fragment of a monoclonal antibody to GPIIb/IIIa (9), and tirofiban and eptifibatide, heterocyclic organic compounds (10,11).

Disintegrins that contain RGD or Lys-Gly-Asp (KGD) sequences have also been identified in snake venoms (8). Naturally occurring disintegrins could provide a template for the development of synthetic peptide antagonists. Within that context, purified and characterized snake venom disintegrins could be used in clinical trials and studies of platelet aggregation.

The aim of this study was purification, partial characterization, and analysis of anti-platelet effect of the disintegrin from the venom of Echis multisquamatis (PAIEM).

MATERIAL AND METHODS

Material

Platelet-rich plasma samples were obtained from the blood of healthy donors. Each experiment was replicated using platelets from the blood of three different donors. Volunteers signed informed consent prior to blood sampling according to the Helsinki declaration. Platelet-rich plasma was prepared from human citrated blood by centrifugation at 1000 rpm for 20 min. Washed platelets were obtained from platelet-rich plasma by centrifugation for 15 min at 1500 rpm and re-suspended in 0.004 M HEPES buffer (N-(2-hydroxyethyl)-piperazine-N’-2-ethanesulfonic acid) of pH 7.4 (0.137 M NaCl, 0.003 M KCl, 0.001 M MgCl$_2$, 0.006 M glucose, 0.003 M NaH$_2$PO$_4$).

Mouse CD61 monoclonal antibody, goat anti-mouse-horseradish peroxidase conjugated (HRP) antibody, Q-sepharose, Superdex G-75, ABTS (2,2’-azino-di-[3-ethylbenzothiazoline-6 sulfonic acid] diammonium salt), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), HEPES buffer, and Amicon Ultra-0.5 mL Centrifugal Filters (UFC500324, Merck Millipore) were purchased from Sigma-Aldrich (St. Louis, MO, USA). ADP was purchased from Tekhnologija-standard (Russia).

Methods

Size-exclusion chromatography

The crude venom of Echis multisquamatis was dissolved in 0.05 M Tris-HCl buffer of pH 7.4 (tris-buffered saline, TBS) and gel-filtered through Superdex G-75 column. The column volume was 60 ml, with a flow rate of 1 ml/min. Fractions that exhibited anti-aggregatory activity were collected and prepared for the ion-exchange chromatography.

Ion-exchange chromatography

Q-sepharose column was pre-equilibrated with 0.05 M Tris-HCl buffer of pH 8.9. The column volume was 3 ml, with a flow rate of 1 ml/min. The solution was eluted with a step gradient of NaCl, and the fraction that contained low-molecular weight fraction was eluted at the ionic strength of 1 M. The active fraction was further concentrated and desalted using Amicon Ultra-0.5 ml Centrifugal Filters (UFC500324, Merck Millipore).

SDS-PAGE and mass-spectrometry

The molecular weights and purity of PAIEM were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 15% gel according to Laemmli (12). Matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) analysis of purified PAIEM was performed using a Voyager-DE (Applied Biosystems, Foster City, CA, USA). H$^+$-matrix ionization of polypeptides with
sinapine acid (Sigma-Aldrich) was used. Results were analyzed by Data Explorer 4.0.0.0 (Applied Biosystems) (13).

**Flow cytometry**

The shape and granularity of resting platelets in platelet-rich plasma after the incubation with PAIEM vs TBS were monitored by flow cytometer as described elsewhere (14). The suspension of washed human platelets in 0.004 M HEPES buffer of pH 7.4 was incubated with 0.1 mg/mL of PAIEM or the equal volume of TBS for the control in the presence of 0.01 M CaCl₂. Platelet activation was induced by 0.125 National Institute of Health units per mL (NIH/mL) of thrombin (15). Parameters of frontal and orthogonal light-dissipation were monitored for the detection of the change of shape and granularity of platelets during their activation at 1, 1.5, 2, 2.5 minutes from activation point.

**Spectrofluorimetric measurements of platelet degranulation**

Platelet activation was registered with pH-sensitive fluorescent dye acridine orange that is accumulated in secretory granules according to their ΔpH and is released after activation. Platelet-rich plasma with or without addition of 10 μg/mL of PAIEM was preincubated at 37°C for 10 minutes, and fluorescence measurements started after the acridine orange application. Changes in fluorescence intensity were measured in a stirred thermostatted cuvette at excitation and emission wavelengths of 490 and 530 nm, respectively, with slit bands 5 nm each. The ADP (2 μM) was applied at the steady state level of acridine orange fluorescence. The traces were normalized (F/Fₒ) to similar data in the absence of platelets. The exocytotic release was calculated as percentage of total accumulated dye at the steady state conditions.

**Indirect ELISA**

Indirect enzyme-linked immunosorbent assay (ELISA) was used for the analysis of PAIEM interactions with activated platelets. Washed human platelets in 0.004 M HEPES buffer of pH 7.4 were added to the wells of 96-well tissue culture plate (Nunc) and then activated by 30 μM of ADP. Wells were gently washed with HEPES buffer trice. Antibody CD61 (specific to IIb subunit of IIb/IIIa platelet receptor) was added to the first row of wells, to the second row antibody CD61 was added alongside with PAIEM (0.05 mg/mL). Probes were incubated for 1 hour at +37°C, then wells were gently washed thrice with HEPES buffer and secondary antibody goat anti-mouse-HRP was added to all wells. After 1-hour incubation, the activity of HRP was monitored using ABTS (2,2’-azino-di-[3-ethyl-benzothiazoline-6 sulfonic acid] diammonium salt). The optical density of the end product was measured at 416 nm. The competition between PAIEM and CD61 antibody was recorded as the difference in signal received in the presence or absence of PAIEM.

**Cell culture**

The HeLa cells (cervical cancer cells) and mouse aortic endothelial cells (MAEC) were grown in Iscove’s modified Dulbecco’s medium (Sigma) supplemented with 10% fetal bovine serum (FBS) and gentamicin (50 μg/mL). All cells were incubated at 37°C in 5% CO₂. The medium was replaced the next day, and cells were incubated under the same conditions in Iscove’s medium containing 10% FBS, gentamicin (50 μg/mL), and 6 μg/mL PAIEM for 48 hours.

**Cell viability assay**

Cell viability was measured by MTT assay. Cells were plated at 15000 cells per well in 96-well plates and incubated with 100 μL complete medium containing 1 mg/mL MTT at 37°C for 4 hours followed by solubilization with dimethyl sulfoxide (Sigma). The absorbance at 540 nm was measured with a microplate reader. The proliferation was expressed as percentage of the viable cell number of the control (non-treated cells) and PAIEM-treated cells. Cell proliferation rate was calculated as \[(1−\text{OD experimental group})/\text{OD control group}]\times100\% (16).

**Statistical analysis**

Statistical analysis was performed using Microsoft Excel. All assays were performed in series of three replicates and the data were fitted with standard errors using “Statistica 7”. The results were presented as means ± standard error (SD). The difference between the groups was analyzed by one-way ANOVA. The level of statistical significance was set at \(P<0.05\).

**RESULTS**

**Purification of the platelet aggregation inhibitor from Echis multisquamatis venom**

After the crude venom was separated into several fractions by ion-exchange chromatography on Q-Sepharose and the fraction containing PAIEM was purified on Superdex G-75, PAIEM displayed as a single peptide chain on SDS-PAGE profile (Figure 1), since the mobility was the same in the presence and absence of 2% beta-mercaptoethanol.
MALDI-TOF-MS analysis showed a molecular mass of 14.9 kDa (Figure 2).

**PAIEM effect on platelets**

*The inhibitory action of PAIEM*

PAIEM displayed the inhibitory action on platelet aggregation in platelet-rich plasma in dose-dependent manner (Figure 3). The PAIEM IC\textsubscript{50} on ADP-induced platelet aggregation was 10 μg/mL (approximately 7 μM), and maximum inhibition (about 80%) was shown at 50 μg/mL (Figure 3). However, total inhibition could not be attained by raising PAIEM concentration (up to 300 μg/mL).

The longer the incubation time of platelet-rich plasma with PAIEM, the greater was the inhibitory effect of the PAIEM on ADP-induced platelet aggregation (Figure 4). Its inhibitory effect on platelet aggregation reached 90% when the incubation time was prolonged to 12 minutes.

**Platelet activation in the presence of PAIEM**

After showing the inhibitory action of PAIEM on platelet aggregation, it was mandatory to know whether PAIEM inhibits activation of platelets. To achieve this goal, we studied thrombin-induced activation of washed platelets in the presence of PAIEM. Dimethyl sulfoxide (DMSO) of 1% was chosen as the positive control. It presumably prevents platelet activation as an inhibitor of cyclooxygenase-1 (17).
Platelets without blood components were incubated with 50 μg/mL of PAIEM or equivalent volume of DMSO and then activated by 0.125 NIH/mL thrombin. The activation was recorded by flow cytometry, which allows estimating the size of the cells (the change of front light scattering) and the granularity of their cytoplasm (the degree of lateral light scattering) (18). Since the activation of platelets is accompanied by changes in their shape and granulation, the change of front and lateral light scattering showed the level of platelet activation (Figure 5).

Two minutes after the stimulation, thrombin reduced the quantity of platelets in zone of resting cells to 18 ± 5% in control probe (Figure 5, panel A2) and to 16 ± 8% in probe with PAIEM (Figure 5, panel A2). Meanwhile, DMSO distinctly inhibited platelet activation – the level of resting platelets in probe with 1% DMSO was 32 ± 6% (Figure 5, panel C2).

Thus, we assumed that PAIEM does not affect platelet response to thrombin stimulation. We also tested platelet degranulation in the presence of PAIEM by applying the spectrofluorimetric registration of release of granular constituents using pH-sensitive fluorescent dye acridine orange (19).

The effect of PAIEM per se on the acidification of platelet secretory granules was estimated at the steady state conditions of pH-sensitive dye accumulation. The application of PAIEM (50 μg/mL) or TBS in equal volume did not affect the proton gradient of platelet secretory granules. Then platelets were stimulated by ADP (2.5 μM) to detect the release of secretory granules constituents. The degranulation was estimated as percentage of dye release from the total accumulated acridine orange. The comparative analysis showed that ADP-stimulated platelet degranulation was not affected by PAIEM (Figure 6). Thus, we assumed that PAIEM inhibits platelet aggregation and does not affect platelet degranulation or agonist-induced reactivity.

Effect of PAIEM on anti-IIb binding to activated platelets

The principal platelet receptor, providing formation and stabilization of fibrin-platelet thrombus, is GPIIb/IIIa. The activation of platelets triggers a conformational change in the receptor GPIIb/IIIa that leads to the formation of a high-affinity ligand-binding state (20). Multiple binding of fibrinogen molecule to GPIIb/IIIa receptors is a crucial process in platelet aggregation.

Therefore the possible interaction of PAIEM and GPIIb/IIIa was analyzed. For this purpose activated platelets were adsorbed on the surface. The binding of anti-GPIIb to GPIIb/IIIa receptors of adhered platelets was estimated in the presence or absence of PAIEM by ELISA using labeled goat anti-mouse antibody. We showed that PAIEM significantly
inhibited the binding of anti-GPIIb antibodies to activated platelets (Figure 7A, B) and assumed that PAIEM prevented platelet aggregation via interaction with GPIIb/IIIa and so was probably an GPIIb/IIIa antagonist.

Effect of PAIEM on proliferation of HeLa and MAIEC cells in cell culture

After showing that PAIEM was a classical disintegrin that inhibited platelet aggregation by binding to GPIIb/IIIa integrins of platelets, we tested the action of PAIEM on proliferation activity on HeLa and MAIEC cells. PAIEM was used at 6 µg/mL that is near IC₅₀ for ADP-induced platelet aggregation. Proliferation index was analyzed as the main parameter of cell division and functionality.

Cell viability after treatment with 6 µg/mL of PAIEM was evaluated by the MTT assay. After 48 hours of incubation, addition of PAIEM decreased the proliferative index by 54% compared to the control group (Figure 8).

DISCUSSION

In the present study, we isolated and purified a novel disintegrin from *Echis multisquamatis* snake venom by two-step chromatography to homogeneity confirmed by SDS-PAGE and determined that the molecular weight of the PAIEM was 14.9 kDa. We also characterized the PAIEM inhibitory activity on human platelets, finding that PAIEM dose-dependently inhibited ADP-induced platelet aggregation with IC₅₀ of 10 µg/mL (approximately 7 μM). Typically, the IC₅₀ values of disintegrins vary from 30 to 300 nM. However, in our study, PAIEM exerted its action without the necessary preincubation with platelet-rich plasma, although its inhibitory effect could be slightly increased by incubation up to 12 minutes.

Disintegrins are antagonists of integrin receptors that inhibit their interaction with individual ligands, and in this way play important role in many biological processes including platelet aggregation, inflammation, atherosclero-

**FIGURE 5.** Flow cytometry of washed human platelets activated by 0.125 NIH/mL of thrombin. 1–3 – 1, 2, and 3 minutes after the stimulation, respectively. A. – control probe; B. – in the presence of 50 µg/mL of platelet aggregation inhibitor from the *Echis multisquamatis* (PAIEM) snake venom; C. – in the presence of 1% dimethyl sulfoxide as the inhibitor of platelet activation. SS – side light scattering, parameter of platelets granulation; FS – frontal light scattering, parameter of platelets shape. Traces are typical for 3 independent experiments made in triplicate.
FIGURE 6. The acidification of platelets secretory granules and the release of granule constituents during adenosine diphosphate (ADP)-induced activation in the presence of platelet aggregation inhibitor from the *Echis multisquamatis* (PAIEM) snake venom. Platelets were loaded with pH-sensitive fluorescent dye acridine orange and stimulated with 2 μM of ADP in the presence or absence of PAIEM. Traces are typical for 5 independent experiments. A – after the addition of equivalent amount of buffer; B – in the presence of 10 μg/mL of PAIEM; C – in the presence of 1% dimethyl sulfoxide; D – summarized enlarged fragment of graphics A-C. Traces are typical for 3 independent experiments performed 5 times each.

FIGURE 7. A. Scheme of experiment that confirmed the platelet aggregation inhibitor from the *Echis multisquamatis* (PAIEM) snake venom binding to glycoprotein (GP)IIb/IIIa. Washed human platelets were added to the wells of 96-well tissue culture plate and then activated by 30 μM of adenosine diphosphate. Antibody CD61 (specific to IIb subunit of IIb/IIIa platelet receptor) was added to the first row of wells, antibody CD61 was added to the second row alongside with PAIEM (0.05 mg/mL). B. Enzyme-linked immunosorbent assay of anti-GPIIb binding to activated platelets in the presence of PAIEM. Boxes and whiskers represent the mean values ± standard error (data of 3 typical experiments performed 5 times each), *P < 0.05 as compared to the control.
It is well known that fibrinogen binds to the exposed integrin GPIIb/IIIa on the platelet surface and mediates platelet interaction and aggregation (24). Disintegrin proved to interact with integrin GPIIb/IIIa and act as fibrinogen receptor antagonist. Thus, disintegrins can inhibit platelet aggregation stimulated by several agonists including ADP, thrombin, and collagen. For example, the disintegrin crototoxstatin significantly prevents reocclusion in the canine carotid arterial thrombosis model (25,26). There are several reports on disintegrins from the venom of Echis multisquamatis. Previously, a C-lectin type antagonist of collagen GPIIb receptor (EMS16) with molecular weight of approximately 33 kDa was purified and characterized (27-29). Protein with the same molecular weight was reported as fibrinogenase with platelet-modulating activity resulted from cleavage of N-terminal portions of Bβ-chain of fibrinogen (30).

Another low-molecular weight protein with anti-aggregatory activity was purified from the Echis multisquamatis venom. Authors determined the molecular weight of the protein as 5.7 kDa (31). It was characterized as anti-GPIIb/IIIa RGD-containing peptide with IC$_{50}$ determined as 97 nM (32).

To summarize results, the low-molecular weight protein from Echis multisquamatis venom was shown to be an inhibitor of platelet aggregation. Isolated inhibitor effectively suppresses platelet aggregation in platelet-rich plasma. It did not affect platelet activation or degranulation but prevented platelet aggregation by inhibiting of fibrinogen binding to GPIIb/IIIa receptor. We also showed a pronounced inhibition of HeLa cells proliferation by PAIEM. We can assume that PAIEM inhibited the viability of HeLa cells possibly by blocking their integrin interactions. We can also assume that PAIEM could be a potential platform for the development of anti-thrombotic drugs as well as anti-proliferative agents in anti-cancer therapy. Further studies of PAIEM action on cancer cells will help us to evaluate the possible use of this polypeptide in anti-cancer therapy.

Acknowledgment Authors cordially acknowledge Prof. Serhiy Komisarenko for his general support of studies of snake venom proteins.

Funding This work was carried out within the framework of the basic research topic of the Palladin Institute of Biochemistry of NAS of Ukraine “Study of regulation mechanisms of blood coagulation and fibrinolysis interplay with vascular and platelet haemostasis”.

Ethical approval was received from the ethics committee of the Palladin Institute of Biochemistry of NAS of Ukraine (21.06.2016, NB).

Declaration of authorship VC developed experiments on platelet aggregation and indirect ELISA. NP designed and performed cell culturing and MTT-test. DK performed flow-cytometry study. OH and TC purified PAIEM. UK performed spectrofluorimetry. AR obtained MALDI-TOF analysis. EL, TP and LH substantially contributed to the study design and acquisition of data. All authors substantially contributed to the analysis and interpretation of data, as well as the drafting of the article. All authors approved the final version of the article to be published.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1 Jackson SP. The growing complexity of platelet aggregation. Blood. 2007;109:5087-95. Medline:17311994 doi:10.1182/blood-2006-12-027698
2 Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res. 2006;99:1293-304. Medline:17158345 doi:10.1161/01.RES.0000251742.71301.16
3 Wijeyeratne YD, Hepinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011;72:647-57.
Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113:340-5. Medline:14755328 doi:10.1172/JCI20986

Schröter K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23:349-56. Medline:9263351 doi:10.1055/s-2007-96108

Fontana P, Zufferey A, Daali Y, Reny JL. Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res. 2014;7:29-38. Medline:24353037 doi:10.1007/s12265-013-9529-1

Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol. 2011;72:634-46. Medline:21649691 doi:10.1111/j.1365-2125.2011.04034.x

Schneider DJ. Antiplatelet therapy: glycoprotein Iib/IIa antagonists. Br J Clin Pharmacol. 2011;72:672-82. Medline:21906121 doi:10.1111/j.1365-2125.2010.03879.x

Ibbotson T, McGavin JK, Goa KL. Aciximab: an updated review of a novel agent for drug eluting stents? Biochem Biophys Res Commun. 2009;376:200-5. Medline:19385958 doi:10.1016/j.bbrc.2009.02.066

Juwnama YB, Suryapranata H, Ottervanger JP, van’t Hof AW. Tirofiban for myocardial infarction. Expert Opin Pharmacother. 2010;11:861-6. Medline:20210689 doi:10.1517/14656561003690005

Zeymer U, Wienbergen H. A review of clinical trials with epifibatide in cardiology. Cardiovasc Drug Rev. 2007;25:301-15. Medline:18078431

Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-5. Medline:5432063 doi:10.1016/0041-0101(70)90227-0

Chapman JR. Mass Spectrometry of Proteins and Peptides, Humana Press. 2000:538.

Pelagalli A, Scala G, Pero ME, Morabito P, Mastellone V, Lombardi PL, et al. Platelet aggregation and flow cytometry analysis of canine platelet rich plasma. Rev Med Vet (B Aires). 2008;10:481-4.

Gryshchuk V, Galagan N. Silica nanoparticles effects on blood coagulation proteins and platelets. Biochemistry Research International. 2016;2016:2959414. doi:10.1155/2016/2959414

Gao W, Chen S-R, Li H. Methylprednisolone exerts neuroprotective effects by regulating autophagy and apoptosis. Neural Regen Res. 2016;11:823-8. Medline:27335569 doi:10.4103/1673-5374.182711

Asmis L, Tanner FC, Sudano I, Lüscher TF, Camici GG. DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents? Biochem Bioph Phys Res Commun. 2010;391:1629-33. Medline:20035720 doi:10.1016/j.bbrc.2009.12.102

Konokhova AI, Yurkin MA, Moskalensky AE, Chernyshev AV, Tsetovskaya GA, Chikova ED, et al. Light-scattering flow cytometry for identification and characterization of blood microparticles. J Biomed Opt. 2012;17:057006. Medline:22612145 doi:10.1117/1. JBO.17.5.057006

Kasatkina LA, Borisova TA. Glutamate release from platelets: exocytosis versus glutamate transporter reversal. Int J Biochem Cell Biol. 2013;45:2585-95. Medline:23994539 doi:10.1016/j. iccel.2013.08.004

Fullard JF. The role of the platelet glycoprotein Iib/IIa in thrombosis and haemostasis. Curr Pharm Des. 2004;10:1567-76. Medline:15134555 doi:10.2174/138161204384682

Swenson S, Ramu S, Markland FS. Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des. 2007;13:2860-71. Medline:17979731 doi:10.2174/138161207782023793

Minea R, Swenson S, Costa F, Chen TC, Markland FS. Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent. Pathophysiol Haemost Thromb. 2005;34:177-83. Medline:16707923 doi:10.1159/000092419

Swenson S, Costa F, Ernst W, Fuji G, Markland FS. Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. Pathophysiol Haemost Thromb. 2005;34:169-76. Medline:16707922 doi:10.1159/000092418

Markland FS. Snake venoms and the hemostatic system. Toxicon. 1998;36:1749-800. Medline:9839663 doi:10.1016/S0041-0101(98)00126-3

Markland FS. A snake venom disintegrin prevents reocclusion following thrombolysis in a canine carotid artery thrombosis model and blocks melanoma metastasis. Toxicon. 1996;34:321. Medline:9634641 doi:10.1016/S0041-0101(95)80896-3

Pyrko P, Wang W, Markland FS, Swenson SD, Schmitmeier S, Schönhal AH, et al. The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. J Neurosurg. 2005;103:526-37. Medline:16235686 doi:10.3171/jns.2005.103.3.0526

Marcinkiewicz C, Lobb RR, Marcinkiewicz MM, Daniel JL, Smith JB, Dangelmaier C, et al. Isolation and characterization of EMS16, an antagonist of collagen receptor (GPIa/IIa) from the venom of Echis multisquamatus. J Biochem. 2003;134:19-23. Medline:12944366 doi:10.1093/jb/mvg108

Swenson S, Costa F, Ernst W, Fuji G, Markland FS. Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent. Pathophysiol Haemost Thromb. 2005;34:177-83. Medline:16707923 doi:10.1159/000092419

Swenson S, Costa F, Ernst W, Fuji G, Markland FS. Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. Pathophysiol Haemost Thromb. 2005;34:169-76. Medline:16707922 doi:10.1159/000092418

Markland FS. Snake venoms and the hemostatic system. Toxicon. 1998;36:1749-800. Medline:9839663 doi:10.1016/S0041-0101(98)00126-3

Markland FS. A snake venom disintegrin prevents reocclusion following thrombolysis in a canine carotid artery thrombosis model and blocks melanoma metastasis. Toxicon. 1996;34:321. Medline:9634641 doi:10.1016/S0041-0101(95)80896-3

Pyrko P, Wang W, Markland FS, Swenson SD, Schmitmeier S, Schönhal AH, et al. The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. J Neurosurg. 2005;103:526-37. Medline:16235686 doi:10.3171/jns.2005.103.3.0526

Marcinkiewicz C, Lobb RR, Marcinkiewicz MM, Daniel JL, Smith JB, Dangelmaier C, et al. Isolation and characterization of EMS16, a C-lectin type protein from Echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin. Biochemistry. 2000;39:9859-67. Medline:10933804 doi:10.1021/bi000428a

Okuda D, Horii K, Mizuno H, Morita T. Characterization and preliminary crystallographic studies of EMS16, an antagonist of collagen receptor (GPla/IIa) from the venom of Echis multisquamatus. J Biochem. 2003;134:19-23. Medline:12944366 doi:10.2174/138161207782023793

Horii K, Okuda D, Morita T, Mizuno H. Structural characterization of EMS16, an antagonist of collagen receptor (GPla/IIa) from the venom of Echis multisquamatus. Biochemistry. 2003;42:12497-502.
30 Chernyshenko V, Platonova T, Makogonenko Y, Rebriev A, Mikhailovska L, Chernyshenko T, et al. Fibrin(ogen)olytic and platelet modulating activity of a novel protease from the Echis multisquamatis snake venom. Biochimie. 2014;105:76-83. Medline:25046629 doi:10.1016/j.biochi.2014.06.015

31 Trikha M, Rote WE, Manley PJ, Lucchesi BR, Markland FS. Purification and characterization of platelet aggregation inhibitors from snake venoms. Thromb Res. 1994;73:39-52. Medline:8178312 doi:10.1016/0049-3848(94)90052-3

32 Okuda D, Nozaki C, Sekiya F, Morita T. Comparative biochemistry of disintegrins isolated from snake venom: consideration of the taxonomy and geographical distribution of snakes in the genus Echis. J Biochem. 2001;129:615-20. Medline:11275562 doi:10.1093/oxfordjournals.jbchem.a002898